Funding Support and Author Disclosures Dr Mehran has received institutional research payments from Abbott, Abiomed, Alleviant Medical, AM-Pharma, Applied Therapeutics, Arena, AstraZeneca, BAIM, Bayer, Beth Israel Deaconess, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CellAegis, CeloNova, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Duke University, Element Science, Humacyte, Insel Gruppe AG, Janssen, Magenta, Medtronic, Novartis, OrbusNeich, Philips, Vivasure, and Zoll; has received personal fees from Boston Scientific, California Institute for Regenerative Medicine (CIRM), Cine-Med Research, Janssen, and WebMD; has received consulting fees paid to the institution from Idorsia Pharmaceuticals, Medtronic, Novartis, and Philips; has equity <1% in Applied Therapeutics, Elixir Medical, STEL, and ControlRad (spouse); has served on the scientific advisory board for the American Medical Association, American College of Cardiology (Board of Trustees Member), Society for Cardiovascular Angiography and Interventions (Women in Innovations Committee Member), and Biosensors (spouse); and has served on Faculty CRF (no fee). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.